Erik Reuter wrote:
It was clear what you meant before your clarification, just not relevant. You can obviously comment on publicly available information,
In my experience (and I have a great deal of it), it is very wise to stay well clear of the *appearance* of impropriety. To do otherwise is a seriously career-limiting move.
Have you ever worked for a public company and been privy to significant insider information? Ever been a consultant in that situation, which tends to raise the stakes even higher?
I'm quite willing to consider your opinions on whether this is a good system or not, but I hear you denying the existence of such rules, which strikes me as naive posturing.
Having said all that, I'll add that I am no fan of the big pharmaceutical companies (and at least one is a client of ours, so I'm sticking my neck out now). I've seen too much evidence of questionable marketing tactics to be comfortable.
Nick
_______________________________________________ http://www.mccmedia.com/mailman/listinfo/brin-l
